Radical cell therapy tested for Tough-to-Treat autoimmune illnesses

This early-stage study is testing the safety and initial effectiveness of a new cell therapy called BZE2204 for adults with severe autoimmune diseases that have not improved with standard treatments. The therapy involves modifying a patient's own immune cells to target and potentially reset the faulty immune response causing diseases like lupus, myositis, or immune thrombocytopenia. Researchers will give the modified cells to about 20 participants and closely monitor them for side effects and any signs of improvement over a year.